Results 81 to 90 of about 71,128 (257)

Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey

Arthritis Care &Research, EarlyView.
Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa, Yicheng Mu, Marie Hudson, Janet Pope   +3 more
wiley   +1 more source

Statistical analysis plan for a pragmatic randomised controlled trial comparing enhanced acceptance and commitment therapy plus ( +) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial

Trials
Background The aim of the SURECAN trial is to evaluate a person-centred intervention, based on Acceptance and Commitment Therapy (ACT Plus ( +)), for people who have completed treatment for cancer with curative intent, but are experiencing poor quality ...
Clare Robinson, Trudie Chalder, Paul McCrone, Olivier Quintin, Evdoxia Gkaintatzi, Imran Khan, Stephanie J. C. Taylor, on behalf of the SURECAN GROUP   +7 more
doaj   +1 more source

Pragmatic clinical trials and the consent process

Research Ethics Review, 2018
Pragmatic clinical trials (PCTs) are a relatively new methodological approach to the execution of clinical research that can increase research efficiency and provide access to unique data.
Blake Murdoch, Timothy Caulfield
doaj   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort

Arthritis Care &Research, Accepted Article.
Objective JAK inhibitors (JAKis) have shown promising effects in early‐phase studies of SSc. We aimed to assess the safety and explore effectiveness of JAKis compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the EUSTAR cohort was performed.
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P Denton, Madelon C Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Frailty Predicts Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis

Arthritis Care &Research, Accepted Article.
Background/Objective Rheumatoid arthritis (RA) is associated with an increased risk of frailty and osteoporosis, but the relationship between frailty and incident osteoporotic fractures in RA is underexplored. Methods Data were from the Veterans Affairs Rheumatoid Arthritis (VARA) Registry.
Katherine D. Wysham, Hannah F. Brubeck, Aaron Baraff, Punyasha Roul, Namrata Singh, James S. Andrews, Grant W. Cannon, Gary A. Kunkel, Ted R. Mikuls, Bryant R. England, Dolores M. Shoback, Patricia P. Katz, Jose M. Garcia, Ariela R. Orkaby, Joshua F. Baker   +14 more
wiley   +1 more source

Immunoinflammatory Mechanisms and Biocompatibility of Bioactive Dental Biomaterials: From Fundamental Insights to Clinical Translation

Advanced Healthcare Materials, EarlyView.
Surface‐host dialogue at the implant interface governs biological fate and osseointegration. Surface physicochemical properties of titanium (Ti) dental implants, including microgrooves, nanopatterns, nanotopography, roughness, and wettability, modulate the initial adsorption of proteins and the formation of a dynamic biointerface.
Daniela Moreira Cunha, Amanda Paino Santana, Marta Maria Alves Pereira, Mariana Martins Guerreiro, Jose Mauro Granjeiro, Jamil Awad Shibli, Jeroen J. J. P. van den Beucken, Anton Sculean, Rafael Scaf de Molon, Erica Dorigatti de Avila   +9 more
wiley   +1 more source

Public perspective on potential treatment intervention harm in clinical trials—terminology and communication

Trials
Background Randomised controlled trials (RCTs) are typically designed to determine beneficial intervention effects. In addition, an important aspect of every trial is to collect data on any potential harmful effects, with the aim of ensuring that the ...
Rachel Phillips, Dongquan Bi, Beatriz Goulão, Marie Miller, Malak El-Askary, Oluyemi Fagbemi, Curie Freeborn, Maria Giammetta, Noura El Masri, Peter Flockhart, Manos Kumar, Mike Melvin, Dianne Murray, Anthony Myhill, Laila Saeid, Shanice Thomas, Graeme MacLennan, Victoria Cornelius   +17 more
doaj   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

What is the impact on recruitment of a shortened compared with a standard-length participant information leaflet? PROMETHEUS in IBD-BOOST: study within a trial, a decentralised UK randomised controlled trial

Trials
Background Participant Information Leaflets (PILs) are lengthy and increasingly complex, and could deter research participation. A shortened PIL may be more appealing as it is likely to provide a more a manageable volume of information. Previous research
L. Miller, A. Hart, F. Cléirigh-Büttner, C. Arundel, T. Hamborg, S. McGuinness, R. Moss-Morris, A. Parker, C. Relton, I. Stagg, L. Sweeney, V. Wileman, Z. Zenasni, C. Norton   +13 more
doaj   +1 more source

Register or electronic health records enriched randomized pragmatic trials: The future of clinical effectiveness and cost-effectiveness trials?

Nordic Journal of Health Economics, 2015
For many interventions in health care, there is limited information on efficacy, safety and cost-effectiveness even long after they have been implemented. To decide between treatments, the randomized controlled trial (RCT) provides the strongest evidence.
Joakim Ramsberg, Martin Neovius
doaj   +1 more source